EQUITY INVESTMENTS	12 Months Ended
Dec. 31, 2021
Equity Method Investments and Joint Ventures [Abstract]
EQUITY INVESTMENTS	EQUITY INVESTMENTSEastman owns a 50 percent or less interest in joint ventures which are accounted for under the equity method. These include a 45 percent interest in a joint venture with China National Tobacco Corporation that manufactures acetate tow in Hefei, China. The Company owns a 50 percent interest in a joint venture that has a manufacturing facility in Nanjing, China. The Nanjing facility produces Eastotac™ hydrocarbon tackifying resins for pressure-sensitive adhesives, caulks, and sealants, which is expected to be sold in 2022 as part of the previously announced definitive agreement the Company entered into to sell the adhesives resins business. For additional information see, Note 2, "Divestiture and Business Held for Sale". These joint ventures also include a joint venture with a 50 percent interest for the manufacture of compounded cellulose diacetate ("CDA") in Shenzhen, China. CDA is a bio-derived material, which is used in various injection molded applications, including but not limited to ophthalmic frames, tool handles, and other end-use products. At December 31, 2021 and 2020, the Company's total investment in these joint ventures was $96 million and $111 million, respectively, included in "Other noncurrent assets" in the Consolidated Statements of Financial Position.

EQUITY INVESTMENTS

12 Months Ended

Dec. 31, 2021

Equity Method Investments and Joint Ventures [Abstract]

EQUITY INVESTMENTSEastman owns a 50 percent or less interest in joint ventures which are accounted for under the equity method. These include a 45 percent interest in a joint venture with China National Tobacco Corporation that manufactures acetate tow in Hefei, China. The Company owns a 50 percent interest in a joint venture that has a manufacturing facility in Nanjing, China. The Nanjing facility produces Eastotac™ hydrocarbon tackifying resins for pressure-sensitive adhesives, caulks, and sealants, which is expected to be sold in 2022 as part of the previously announced definitive agreement the Company entered into to sell the adhesives resins business. For additional information see, Note 2, "Divestiture and Business Held for Sale". These joint ventures also include a joint venture with a 50 percent interest for the manufacture of compounded cellulose diacetate ("CDA") in Shenzhen, China. CDA is a bio-derived material, which is used in various injection molded applications, including but not limited to ophthalmic frames, tool handles, and other end-use products. At December 31, 2021 and 2020, the Company's total investment in these joint ventures was $96 million and $111 million, respectively, included in "Other noncurrent assets" in the Consolidated Statements of Financial Position.